Walleye Capital
ELEV

Walleye Capital’s Elevation Oncology ELEV Stock Holding History

Walleye Capital’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-615,837
Closed -$1.66M – 5421
2024
Q2 		$1.66M Sell
615,837
-170,747
-22% -$643K ﹤0.01% 2285
2024
Q1 		$4.04M Buy
+786,584
New +$2.55M 0.01% 1453
2023
Q4 		– Sell
-148,887
Closed -$98.7K – 5088
2023
Q3 		$98.7K Buy
148,887
+45,257
+44% +$45.8K ﹤0.01% 3947
2023
Q2 		$158K Sell
103,630
-330,818
-76% -$872K ﹤0.01% 3223
2023
Q1 		$825K Buy
+434,448
New +$561K 0.01% 1306

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Walleye Capital's ELEV Position: Q3 2024 in Review

Walleye Capital sold out of Elevation Oncology (ELEV) in Q3 2024, closing a stake of 615,837 shares — an estimated $1.66M sold.

Walleye Capital first reported a position in ELEV in Q1 2023 and held it in 5 quarters. The position peaked at $4.04M in Q1 2024. 68 funds tracked by Wall St. Rank hold ELEV as of Q3 2024.

  • Walleye Capital reported no remaining Elevation Oncology position as of Q3 2024 after selling out during the quarter.
  • Walleye Capital sold 615,837 Elevation Oncology shares in Q3 2024, an estimated $1.66M.
  • Walleye Capital first reported a position in Elevation Oncology in Q1 2023 and held it in 5 quarters.
  • Walleye Capital's Elevation Oncology position peaked at $4.04M in Q1 2024.
  • 68 funds tracked by Wall St. Rank held Elevation Oncology as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.